[go: up one dir, main page]

DE60130644D1 - R-2-(aminoaryl)-propionsäure-amide und ihre verwendung zur aktivierung von leukocyten - Google Patents

R-2-(aminoaryl)-propionsäure-amide und ihre verwendung zur aktivierung von leukocyten

Info

Publication number
DE60130644D1
DE60130644D1 DE60130644T DE60130644T DE60130644D1 DE 60130644 D1 DE60130644 D1 DE 60130644D1 DE 60130644 T DE60130644 T DE 60130644T DE 60130644 T DE60130644 T DE 60130644T DE 60130644 D1 DE60130644 D1 DE 60130644D1
Authority
DE
Germany
Prior art keywords
aminoaryl
amides
leukocytes
activation
propionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130644T
Other languages
English (en)
Other versions
DE60130644T2 (de
Inventor
Marcello Allegretti
Riccardo Bertini
Cinzia Bizzarri
Vilma Sabbatini
Gianfranco Caselli
Maria Candida Cesta
Carmelo Gandolfi
Francesco Colotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe PhaRMa SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe PhaRMa SpA filed Critical Dompe PhaRMa SpA
Publication of DE60130644D1 publication Critical patent/DE60130644D1/de
Application granted granted Critical
Publication of DE60130644T2 publication Critical patent/DE60130644T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DE60130644T 2000-04-14 2001-04-11 R-2-(aminoaryl)-propionsäure-amide und ihre verwendung zur aktivierung von leukocyten Expired - Lifetime DE60130644T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2000MI000836A IT1318466B1 (it) 2000-04-14 2000-04-14 Ammidi di acidi r-2-(amminoaril)-propionici, utili nella prevenzionedell'attivazione leucocitaria.
ITMI20000836 2000-04-14
PCT/EP2001/004137 WO2001079189A2 (en) 2000-04-14 2001-04-11 'amides of r-2-(aminoaryl)-propionic acids for use in theprevention of leucocyte activation'

Publications (2)

Publication Number Publication Date
DE60130644D1 true DE60130644D1 (de) 2007-11-08
DE60130644T2 DE60130644T2 (de) 2008-08-14

Family

ID=11444862

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130644T Expired - Lifetime DE60130644T2 (de) 2000-04-14 2001-04-11 R-2-(aminoaryl)-propionsäure-amide und ihre verwendung zur aktivierung von leukocyten

Country Status (15)

Country Link
US (1) US7217707B2 (de)
EP (1) EP1276732B1 (de)
AT (1) ATE374193T1 (de)
AU (2) AU4653901A (de)
CA (1) CA2420585C (de)
CY (1) CY1107078T1 (de)
CZ (1) CZ303407B6 (de)
DE (1) DE60130644T2 (de)
DK (1) DK1276732T3 (de)
ES (1) ES2292574T3 (de)
IT (1) IT1318466B1 (de)
NO (1) NO325650B1 (de)
PT (1) PT1276732E (de)
RU (1) RU2268263C2 (de)
WO (1) WO2001079189A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
JP3801559B2 (ja) 2002-12-26 2006-07-26 ソニー株式会社 通信装置および方法、記録媒体、並びにプログラム
EP1457485A1 (de) 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonsäuren, deren Derivate sowie sie enthaltenden pharmazeutischen Zubereitungen
EP1579859B1 (de) * 2004-03-25 2006-12-13 DOMPE' pha.r.ma s.p.a. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH526538A (de) * 1967-07-22 1972-08-15 Merck Patent Gmbh Verfahren zur Herstellung von Aminophenylessigsäure-Derivaten
SU436049A1 (de) * 1971-01-25 1974-07-15 Е. М. хман , Л. Б. Гвадыбадзе
IT1193955B (it) * 1980-07-22 1988-08-31 Real Di Alberto Reiner S A S Derivati ammidici dell'acido p-isobutilfenilpropionico, procedimento per la loro preparazione e relative composizioni farmaceutici
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
IT1303685B1 (it) * 1998-10-30 2001-02-23 Dompe Spa Procedimento per la preparazione di acidi alfa-arilalcanoici
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.

Also Published As

Publication number Publication date
US20040186146A1 (en) 2004-09-23
ATE374193T1 (de) 2007-10-15
US7217707B2 (en) 2007-05-15
CA2420585A1 (en) 2001-10-25
ITMI20000836A0 (it) 2000-04-14
IT1318466B1 (it) 2003-08-25
PT1276732E (pt) 2007-12-06
CA2420585C (en) 2009-11-03
NO20026220D0 (no) 2002-12-23
ITMI20000836A1 (it) 2001-10-14
EP1276732B1 (de) 2007-09-26
AU4653901A (en) 2001-10-30
NO20026220L (no) 2002-12-23
WO2001079189A3 (en) 2003-10-09
HK1051035A1 (en) 2003-07-18
WO2001079189A2 (en) 2001-10-25
DK1276732T3 (da) 2008-02-25
RU2268263C2 (ru) 2006-01-20
CY1107078T1 (el) 2012-10-24
ES2292574T3 (es) 2008-03-16
NO325650B1 (no) 2008-06-30
DE60130644T2 (de) 2008-08-14
EP1276732A1 (de) 2003-01-22
CZ20023773A3 (cs) 2003-03-12
AU2001246539B2 (en) 2005-06-02
CZ303407B6 (cs) 2012-09-05

Similar Documents

Publication Publication Date Title
EE05284B1 (et) 2-arlpropioonhappe amiidide R-enantiomeerid, nende valmistamismeetod, farmatseutiline kompositsioon ja 2-arlpropioonhapete R-enantiomeerid
EP0468231B1 (de) Guanidine
MXPA03006786A (es) Omega-aminoalquilamidas de los acidos r-2-aril-propionicos como inhibidores de la quimiotaxis de las celulas mononucleadas y polimorfonucleadas.
US20090036420A1 (en) Benzamide derivatives and their use for treating cns disorders
DE60013302T2 (de) Cystein protease inhibitore
JP2010006834A (ja) カルパインインヒビターとしての複素環式的に置換されたアミド
CA2458035A1 (en) Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them
ATE168007T1 (de) Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
CA2347752A1 (en) N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
JP2006526000A (ja) Ｎ型カルシウムチャネル遮断薬としての３−アミノメチル−ピロリジン
NO973035L (no) Hydroksaminsyre-holdige inhibitorer for matriks-metallproteaser
EA199800721A1 (ru) Ингибитор реваскуляризации
CY1107078T1 (el) Αμιδια του r-2-(αμινοαρυλ)-προπιονικου οξεος για χρηση στην προληψη της ενεργοποιησης των λευκοκυτταρων
ATE431735T1 (de) Fusionierte cycloalkyl amid- und carbonsäure- derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
AR027754A1 (es) Nuevo procedimiento para la sintesis de esteres de n-[(s)-1-carboxibutil]-(s)-alanina y aplicacion en la sintesis de perindopril
ATE521589T1 (de) Amidine und derivate davon und pharmazeutische zusammensetzungen, die diese enthalten
MY133525A (en) Ethyl(2s)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate, a process and intermediates for its preparation, and its use asa pharmaceutical
HK1037189A (en) New heterocyclically substituted amides, their production and their use
TH63263A (th) N-[4(1H-อิมิดาซอล-1-อิล)-2-ฟลูออโรฟีนิล]-3-(ไตรฟลูออโรเมทธิล)-1H-ไพราโซล-5-คาร์บอกซาไมด์ ชนิดใหม่ในการเป็นการสารยับยั้งของแฟคเตอร์ Xa
EP1170287A4 (de) Verfahren zur herstellung optisch aktiver, n-substituierter azetidin-2-carbonsäuren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition